These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28626218)

  • 1. Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
    Rinke J; Müller JP; Blaess MF; Chase A; Meggendorfer M; Schäfer V; Winkelmann N; Haferlach C; Cross NCP; Hochhaus A; Ernst T
    Leukemia; 2017 Sep; 31(9):1936-1943. PubMed ID: 28626218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
    Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
    Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
    Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
    Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
    J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
    Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
    Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
    Sakhdari A; Class C; Montalban-Bravo G; Sasaki K; Bueso-Ramos CE; Patel KP; Routbort MJ; Loghavi S; Ok CY; Quesada A; Khoury JD; Konoplev SN; Kantarjian HP; Garcia-Manero G; Medeiros LJ; Kanagal-Shamanna R
    Mod Pathol; 2022 Sep; 35(9):1212-1219. PubMed ID: 35504958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
    Wang J; Ai X; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Hu N; Zhang Y; Xiao Z
    Leuk Res; 2013 Mar; 37(3):305-11. PubMed ID: 23099237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.
    Ball S; Aguirre LE; Jain AG; Ali NA; Tinsley SM; Chan O; Kuykendall AT; Sweet K; Lancet JE; Sallman DA; Hussaini MO; Padron E; Komrokji RS
    Leuk Res; 2023 Jan; 124():106999. PubMed ID: 36542963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double sword role of EZH2 in leukemia.
    Safaei S; Baradaran B; Hagh MF; Alivand MR; Talebi M; Gharibi T; Solali S
    Biomed Pharmacother; 2018 Feb; 98():626-635. PubMed ID: 29289837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
    Sashida G; Iwama A
    Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
    Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
    J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of enhancer of zeste homolog 2 mutations on the prognosis of patients with myelodysplastic syndrome: A meta-analysis.
    Huang X; Wang X
    Medicine (Baltimore); 2020 Aug; 99(34):e21900. PubMed ID: 32846854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.
    Fu Y; Schroeder T; Zabelina T; Badbaran A; Bacher U; Kobbe G; Ayuk F; Wolschke C; Schnittger S; Kohlmann A; Haferlach T; Kröger N
    Eur J Haematol; 2014 Mar; 92(3):189-94. PubMed ID: 24164563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.
    Kawabata KC; Hayashi Y; Inoue D; Meguro H; Sakurai H; Fukuyama T; Tanaka Y; Asada S; Fukushima T; Nagase R; Takeda R; Harada Y; Kitaura J; Goyama S; Harada H; Aburatani H; Kitamura T
    Leukemia; 2018 Feb; 32(2):419-428. PubMed ID: 28720764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.